全球静脉输液市场规模、份额、趋势和成长分析报告（2026-2034年）

预计静脉输液市场将从 2025 年的 198.1 亿美元成长到 2034 年的 409.1 亿美元，2026 年至 2034 年的复合年增长率为 8.39%。

静脉输液市场正稳定成长，主要受住院率上升、慢性病管理以及需要肠外输液的手术数量增加的推动。生理食盐水、葡萄糖和平衡电解质溶液在急诊医学、外科手术和重症监护中的广泛应用支撑了稳定的需求。已开发市场人口老化和新兴经济体医院基础设施的持续改善是推动市场成长的主要因素，而标准化静脉输液疗法的普及则改善了临床疗效，并扩大了市场规模。

关键成长要素包括外科手术量的增加、脱水和败血症发病率的上升，以及在某些临床情况下，平衡结晶溶液比传统生理食盐水更受青睐。日益严格的监管和品管要求促使製造商转向符合GMP规范的生产，以满足严格的无菌和包装标准。面对间歇性供不应求，供应链韧性已成为一项关键挑战，促使製造商投资于冗余产能、区域填充和包装基地，并改善特殊静脉製剂的低温运输物流。

未来前景包括预混合料和客製化静脉输液袋的成长、拓展门诊输液服务以及配方创新（针对特定患者群体量身定制的电解质平衡解决方案）。配备生物感测器的输液帮浦和互联输液管理系统有望为製造商创造更多服务机会。能够保证供应稳定性、展现成本效益高的生产能力并透过临床数据支持医院药品清单的新兴参与企业，将在全球医疗系统对可靠、高品质注射剂的需求不断增长的背景下，扩大市场份额。

目录

第一章：引言

第二章执行摘要

第三章 市场变数、趋势与框架

• 市场谱系展望
• 渗透率和成长前景分析
• 价值链分析
• 法律规范
  • 标准与合规性
  • 监管影响分析
• 市场动态
  • 市场驱动因素
  • 市场限制因素
  • 市场机会
  • 市场挑战
• 波特五力分析
• PESTLE分析

第四章：全球静脉输液市场：依类型划分

• 市场分析、洞察与预测
• 全静脉营养
• 周边静脉营养

第五章：全球静脉输液市场：依成分划分

• 市场分析、洞察与预测
• 碳水化合物
• 维生素和矿物质
• 单剂量胺基酸製剂
• 肠外脂肪乳剂
• 其他作品

第六章：全球静脉输液市场：依年龄组别划分

• 市场分析、洞察与预测
• 儿童
• 成人
• 老年人

第七章 全球静脉输液市场：依应用划分

• 市场分析、洞察与预测
• 营养支持
• 输血
• 体液和电解质平衡
• 其他用途

第八章：全球静脉输液市场：依最终用途划分

• 市场分析、洞察与预测
• 医院和诊所
• 门诊手术中心
• 居家医疗环境

第九章 全球静脉输液市场：依地区划分

• 区域分析
• 北美市场分析、洞察与预测
  • 我们
  • 加拿大
  • 墨西哥
• 欧洲市场分析、洞察与预测
  • 英国
  • 法国
  • 德国
  • 义大利
  • 俄罗斯
  • 其他欧洲国家
• 亚太市场分析、洞察与预测
  • 印度
  • 日本
  • 韩国
  • 澳洲
  • 东南亚
  • 其他亚太国家
• 拉丁美洲市场分析、洞察与预测
  • 巴西
  • 阿根廷
  • 秘鲁
  • 智利
  • 其他拉丁美洲国家
• 中东和非洲市场分析、洞察与预测
  • 沙乌地阿拉伯
  • UAE
  • 以色列
  • 南非
  • 其他中东和非洲国家

第十章 竞争格局

• 最新趋势
• 公司分类
• 供应链和销售管道合作伙伴（根据现有资讯）
• 市场占有率和市场定位分析（基于现有资讯）
• 供应商情况（基于现有资讯）
• 策略规划

第十一章：公司简介

• 主要公司的市占率分析
• 公司简介
  • AdvaCare Pharma
  • Amanta Healthcare
  • Axa Parenterals
  • B. Braun
  • Baxter International
  • Fresenius Kabi
  • Grifols
  • ICU Medical
  • JW Life Science
  • Otsuka Pharmaceutical

The Intravenous Solutions Market size is expected to reach USD 40.91 Billion in 2034 from USD 19.81 Billion (2025) growing at a CAGR of 8.39% during 2026-2034.

The intravenous (IV) solutions market has shown steady expansion driven by rising hospital admissions, chronic disease management, and increased procedural volumes requiring parenteral fluids. Broad use of saline, dextrose, and balanced electrolyte solutions across emergency care, surgery, and critical care underpins consistent demand. Growth is supported by aging populations in developed markets and expanding hospital infrastructure in emerging economies, where access to standardized IV therapies is improving clinical outcomes and supporting market scale-up.

Key drivers comprise increasing surgical procedures, rising incidence of dehydration and sepsis, and a growing preference for balanced crystalloids over traditional saline in certain clinical settings. Regulatory scrutiny and quality-control requirements push manufacturers toward GMP-compliant production with stringent sterility and packaging standards. Supply-chain resilience has become a core concern following episodic shortages; consequently, manufacturers invest in redundant capacity, regional fill-and-finish sites, and improved cold-chain logistics for specialty parenteral formulations.

Future prospects include growth in premixed and customized IV bags, expansion into ambulatory infusion services, and formulation innovations (electrolyte-balanced solutions tailored to specific patient populations). Biosensor-enabled IV pumps and connected infusion management may create adjunct service opportunities for manufacturers. Market entrants who can guarantee supply security, demonstrate cost-effective manufacturing, and support hospital formularies through clinical data will capture incremental share as healthcare systems globally push for reliable, high-quality parenteral therapy supplies.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Type

• Total Parenteral Nutrition
• Peripheral Parenteral Nutrition

By Composition

• Carbohydrates
• Vitamins And Minerals
• Single-Dose Amino Acids
• Parenteral Lipid Emulsion
• Other Compositions

By Age Group

• Pediatric
• Adults
• Geriatric

By Application

• Nutritional Support
• Blood Transfusion
• Fluid And Electrolyte Balance
• Other Applications

By End Use

• Hospitals And Clinics
• Ambulatory Surgery Centers
• Home Care Settings

COMPANIES PROFILED

• AdvaCare Pharma, Amanta Healthcare, Axa Parenterals, B Braun, Baxter International, Fresenius Kabi, Grifols, ICU Medical, JW Life Science, Otsuka Pharmaceutical
• We can customise the report as per your requirements.

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL INTRAVENOUS SOLUTIONS MARKET: BY TYPE 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Type
• 4.2. Total Parenteral Nutrition Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Peripheral Parenteral Nutrition Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL INTRAVENOUS SOLUTIONS MARKET: BY COMPOSITION 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Composition
• 5.2. Carbohydrates Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Vitamins And Minerals Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.4. Single-Dose Amino Acids Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.5. Parenteral Lipid Emulsion Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.6. Other Compositions Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL INTRAVENOUS SOLUTIONS MARKET: BY AGE GROUP 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast Age Group
• 6.2. Pediatric Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. Adults Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.4. Geriatric Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL INTRAVENOUS SOLUTIONS MARKET: BY APPLICATION 2022-2034 (USD MN)

• 7.1. Market Analysis, Insights and Forecast Application
• 7.2. Nutritional Support Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.3. Blood Transfusion Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.4. Fluid And Electrolyte Balance Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.5. Other Applications Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 8. GLOBAL INTRAVENOUS SOLUTIONS MARKET: BY END USE 2022-2034 (USD MN)

• 8.1. Market Analysis, Insights and Forecast End Use
• 8.2. Hospitals And Clinics Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 8.3. Ambulatory Surgery Centers Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 8.4. Home Care Settings Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 9. GLOBAL INTRAVENOUS SOLUTIONS MARKET: BY REGION 2022-2034(USD MN)

• 9.1. Regional Outlook
• 9.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 9.2.1 By Type
  • 9.2.2 By Composition
  • 9.2.3 By Age Group
  • 9.2.4 By Application
  • 9.2.5 By End Use
  • 9.2.6 United States
  • 9.2.7 Canada
  • 9.2.8 Mexico
• 9.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 9.3.1 By Type
  • 9.3.2 By Composition
  • 9.3.3 By Age Group
  • 9.3.4 By Application
  • 9.3.5 By End Use
  • 9.3.6 United Kingdom
  • 9.3.7 France
  • 9.3.8 Germany
  • 9.3.9 Italy
  • 9.3.10 Russia
  • 9.3.11 Rest Of Europe
• 9.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 9.4.1 By Type
  • 9.4.2 By Composition
  • 9.4.3 By Age Group
  • 9.4.4 By Application
  • 9.4.5 By End Use
  • 9.4.6 India
  • 9.4.7 Japan
  • 9.4.8 South Korea
  • 9.4.9 Australia
  • 9.4.10 South East Asia
  • 9.4.11 Rest Of Asia Pacific
• 9.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 9.5.1 By Type
  • 9.5.2 By Composition
  • 9.5.3 By Age Group
  • 9.5.4 By Application
  • 9.5.5 By End Use
  • 9.5.6 Brazil
  • 9.5.7 Argentina
  • 9.5.8 Peru
  • 9.5.9 Chile
  • 9.5.10 South East Asia
  • 9.5.11 Rest of Latin America
• 9.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 9.6.1 By Type
  • 9.6.2 By Composition
  • 9.6.3 By Age Group
  • 9.6.4 By Application
  • 9.6.5 By End Use
  • 9.6.6 Saudi Arabia
  • 9.6.7 UAE
  • 9.6.8 Israel
  • 9.6.9 South Africa
  • 9.6.10 Rest of the Middle East And Africa

Chapter 10. COMPETITIVE LANDSCAPE

• 10.1. Recent Developments
• 10.2. Company Categorization
• 10.3. Supply Chain & Channel Partners (based on availability)
• 10.4. Market Share & Positioning Analysis (based on availability)
• 10.5. Vendor Landscape (based on availability)
• 10.6. Strategy Mapping

Chapter 11. COMPANY PROFILES OF GLOBAL INTRAVENOUS SOLUTIONS INDUSTRY

• 11.1. Top Companies Market Share Analysis
• 11.2. Company Profiles
  • 11.2.1 AdvaCare Pharma
  • 11.2.2 Amanta Healthcare
  • 11.2.3 Axa Parenterals
  • 11.2.4 B. Braun
  • 11.2.5 Baxter International
  • 11.2.6 Fresenius Kabi
  • 11.2.7 Grifols
  • 11.2.8 ICU Medical
  • 11.2.9 JW Life Science
  • 11.2.10 Otsuka Pharmaceutical